ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Winter Conference & Expo
November 15–18, 2026
Phoenix, AZ|Arizona Grand Resort & Spa
Latest Magazine Issues
Aug 2026
Jan 2026
2026
Latest Journal Issues
Nuclear Science and Engineering
October 2026
Nuclear Technology
September 2026
Fusion Science and Technology
August 2026
Latest News
LLNL, Ampera partner to develop thorium-based TRISO fuel
Lawrence Livermore National Laboratory has formed a strategic partnership with Ampera to develop the company’s nuclear fuel concept through a project named THUNDER, for Thorium Unimodal Droplet Ejection for Reactors.
The focus of THUNDER is fabricating TRISO made with kernels of thorium rather than the usual uranium. LLNL and Ampera will evaluate and optimize liquid metal–jetting technology to produce highly uniform, spherical kernels of thorium-232 for later processing into TRISO fuel.
Floyd J. Wheeler, D. Kent Parsons, Brian L. Rushton, David W. Nigg
Nuclear Technology | Volume 92 | Number 1 | October 1990 | Pages 106-117
Technical Paper | Development of Nuclear Gas Cleaning and Filtering Techniques / Fission Reactor | doi.org/10.13182/NT90-A34490
Articles are hosted by Taylor and Francis Online.
Nuclear design studies have been performed for two reactor-based epithermal neutron beams for cancer treatment by neutron capture therapy (NCT). An intermediate-intensity epithermal beam has been designed and implemented at the Brookhaven Medical Research Reactor (BMRR). Measurements show that the BMRR design predictions for the principal characteristics of this beam are accurate. A canine program for research into the biological effects of NCT is now under way at BMRR. The design for a high-intensity epithermal beam with minimal contamination from undesirable radiation components has been finalized for the Power Burst Facility (PBF) at the Idaho National Engineering Laboratory. This design will be implemented when it is determined that human NCT trials are advisable. The PBF beam will exhibit approximately an order of magnitude improvement in absolute epithermal flux intensity over that available in the BMRR, and its angular distribution and spectral characteristics will be more advantageous for NCT. The combined effects of beam intensity, angular distribution, spectrum, and contaminant level allow the desired tumor radiation dose to be delivered in much shorter times than are possible with the currently available BMRR beam, with a significant reduction (factor of 3 to 5) in collateral dose due to beam contaminants.